125 related articles for article (PubMed ID: 33427920)
1. [Intratumoral heterogeneity of gastric cancer-impact on biomarker evaluation].
Halske C
Pathologe; 2020 Dec; 41(Suppl 2):76-82. PubMed ID: 33427920
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Böger C; Krüger S; Behrens HM; Bock S; Haag J; Kalthoff H; Röcken C
Ann Oncol; 2017 May; 28(5):1005-1014. PubMed ID: 28453696
[TBL] [Abstract][Full Text] [Related]
3. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
[TBL] [Abstract][Full Text] [Related]
5. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
6. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
[TBL] [Abstract][Full Text] [Related]
7. HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
Grillo F; Fassan M; Sarocchi F; Fiocca R; Mastracci L
World J Gastroenterol; 2016 Jul; 22(26):5879-87. PubMed ID: 27468182
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma.
Setia N; Ahn S; Han HS; Park DY; Lauwers GY
Hum Pathol; 2019 Dec; 94():64-70. PubMed ID: 31676362
[TBL] [Abstract][Full Text] [Related]
9. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
[TBL] [Abstract][Full Text] [Related]
10. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
[TBL] [Abstract][Full Text] [Related]
11. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
12. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer.
Kurokawa Y; Matsuura N; Kimura Y; Adachi S; Fujita J; Imamura H; Kobayashi K; Yokoyama Y; Shaker MN; Takiguchi S; Mori M; Doki Y
Gastric Cancer; 2015 Oct; 18(4):691-7. PubMed ID: 25224659
[TBL] [Abstract][Full Text] [Related]
13. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
[TBL] [Abstract][Full Text] [Related]
14. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
[TBL] [Abstract][Full Text] [Related]
15. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers in gastric cancer.
Röcken C
J Cancer Res Clin Oncol; 2023 Jan; 149(1):467-481. PubMed ID: 36260159
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing in gastric and gastroesophageal junction adenocarcinomas: role of the gastroenterologist.
Park JY; Dunbar KB; Vemulapalli R; Wang DH; Zhang PJ
Gastrointest Endosc; 2015 Apr; 81(4):977-82. PubMed ID: 25805465
[TBL] [Abstract][Full Text] [Related]
19. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
[TBL] [Abstract][Full Text] [Related]
20. Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens.
Koopman T; de Bock GH; Buikema HJ; Smits MM; Louwen M; Hage M; Imholz ALT; van der Vegt B
Histopathology; 2018 Jan; 72(2):191-200. PubMed ID: 28746978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]